 | | Vol. 15.08 – 5 March, 2024 |
| |
|
|
| The study was conducted among adults with T2D and chronic kidney disease (CKD) initiating sodium-glucose cotransporter 2 (SGLT2) inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
[Jama Network Open] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| The authors used deep RNA-seq analysis, RT-qPCR, western blot, histology, and siRNAs, to characterize the response of human pancreatic beta cells to each cytokine individually and compared the signatures obtained with those present in islets of individuals affected by T1D.
[Diabetolgia] |
| |
|
|
| Researchers successfully engineered an adenosine 5′-triphosphate-responsive manganese-based bacterial material that exhibited an exceptional ability to synergistically activate the cyclic GMP-AMP synthase-stimulator of interferon genes pathway.
[Advanced Materials] |
|
|
|
| In both gemcitabine-resistant pancreatic ductal adenocarcinoma patients and mouse models, the elevated expression level of MACC1-AS1 in the tumors was noted. Overexpression of MACC1-AS1 in pancreatic cancer cells was found to enhance tolerance to gemcitabine and suppress ferroptosis.
[Cell Death Discovery] |
|
|
|
| Investigators treated pancreatic tumor organoids with 4 or 8 Gy of radiation, 10 μM of 5-Fluorouracil, and 100 μM 3-Bromopyruvate, a promising anti-cancer drug, as a single treatment modality, and in combination with RT.
[Cell Death Discovery] |
|
|
|
| The authors found that progesterone receptor, a steroid-responsive nuclear receptor, was highly expressed in PDAC tissues obtained from both patients and transgenic LSL-KrasG12D/+; LSL-Trp53R172H/+; PDX1-cre mice.
[Oncogenesis] |
|  |
|
|
|
| Investigators retrace the history of relevant research on metabolic memory and summarize its salient characteristics. They provide a detailed discussion of the mechanisms by which metabolic memory may be involved in disease development.
[Signal Transduction And Targeted Therapy] |
|
|
|
|
| SN Bioscience Co. Ltd. announced that the US FDA had granted an orphan drug designation for pancreatic cancer for SNB-101, a new polymer nanoparticle drug under development, based on the pre-clinical data of SNB-101 on pancreatic cancer animal model.
[SN BioScience (PR Newswire)] |
|
|
|
|
| March 24 – 29, 2024
Galveston, Texas, United States |
|
|
|
|
|
| | King’s College London – London, England, United Kingdom |
|
|
|
| | King’s College London – London, England, United Kingdom |
|
|
|
| | University of Exeter – Exeter, England, United Kingdom |
|
|
|
| | Virginia Commonwealth University – Richmond, Virginia, United States |
|
|
|
| | City of Hope – Monrovia, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
